用于自身免疫性疾病和其他非肿瘤性疾病的工程化T细胞免疫疗法的进展。
Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases.
作者信息
Huang Qiaolin, Zhu Xiaojian, Zhang Yicheng
机构信息
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.
Key Laboratory of Organ Transplantation, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Ministry of Education, Chinese Academy of Medical Sciences, Wuhan, 430030, Hubei, China.
出版信息
Biomark Res. 2025 Feb 4;13(1):23. doi: 10.1186/s40364-025-00736-8.
Adoptive immunotherapy using engineered T cells expressing chimeric antigen receptors has shown remarkable success in treating patients with hematological malignancies. However, realizing broader therapeutic applications of engineered T cells in other diseases requires further exploration in clinical investigations. In this review, we highlight recent advances in the engineering of T cells in non-oncology areas, including autoimmune and inflammatory diseases, infections, fibrosis, hemophilia, and aging. Chimeric antigen receptor immunotherapy has shown good outcomes in non-oncology areas, but many challenges remain in improving its safety and efficacy and and expanding its application to the treatment of non-oncological diseases.
使用表达嵌合抗原受体的工程化T细胞进行过继性免疫疗法在治疗血液系统恶性肿瘤患者方面已显示出显著成效。然而，要实现工程化T细胞在其他疾病中的更广泛治疗应用，还需要在临床研究中进一步探索。在这篇综述中，我们重点介绍了T细胞工程在非肿瘤领域的最新进展，包括自身免疫性疾病、炎症性疾病、感染、纤维化、血友病和衰老。嵌合抗原受体免疫疗法在非肿瘤领域已显示出良好疗效，但在提高其安全性和有效性以及将其应用扩展到非肿瘤疾病治疗方面仍存在许多挑战。
Zotero 插件